case_images: PMC6264041_01
case_images: Plasma concentration-time curves of carboplatin during the (a) first and (b) second chemotherapy cycle. The time intervals between the carboplatin infusion and the commencement of hemodialysis were 2 h in the first cycle and 1 h in the second cycle of gemcitabine plus carboplatin chemotherapy. Hemodialysis was performed for 3 h in each chemotherapy cycle. AUC: area under the concentration-time curve; HD, hemodialysis
case_images: 40780_2018_124_Fig1_HTML.jpg
case_images: PMC6264041_01_40780_2018_124_Fig1_HTML.jpg
case_images: Fig1
case_images: Sampling points were as follows: immediately after CBDCA infusion, before starting and ending hemodialysis, and 20 and 48 h after CBDCA infusion on day 1 (Fig. 1). CBDCA in the first cycle was 5.96 mg/mL min, which was 19.2% higher than the target AUC (Fig. 1a). Consequently, grade 4 neutropenia and grade 3 thrombocytopenia were observed, according to the National Cancer Institute's Common The measured AUC of CBDCA in the second cycle was 4.97 mg/mL min (Fig. 1b). The CBDCA dose and administration procedure in the third cycle were the same as that in the second cycle.